Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.

NCT07736963 | Recruiting DMC

• 1 other identifier: LGI GLP-1
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the impact of different discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy on bowel preparation quality and the need for repeat colonoscopy, in order to establish appropriate discontinuation recommendations.

Conditions

GLP-1

Keywords

GLP-1

Outcome Measures

Primary Outcomes (1)

• .Incomplete bowel preparation rate(IBP) through BBPS(Boston Bowel Preparation Scale)

  Effect： Primary outcome: 1.Incomplete bowel preparation rate(IBP) through BBPS(Boston Bowel Preparation Scale) (Total BBPS score \< = 5 or score \<= 1 in any segment) Secondary outcomes: 1. Adenoma detection rate (ADR) 2. Detection rate number of advanced adenomas and colorectal serrated lesions 3. Time for scope insertion to cecum and withdrawal from the cecum to rectum. 4. Incidence of adverse events during colonoscopy 5. Weight gain or HSS was recorded after stopping GLP-1 and before colonoscopy

  "From enrollment to the end of Procedure and follow up for 30 days"

Study Arms (2)

GLP-1 stop for 1 week

ACTIVE COMPARATOR

GLP-1 stop for 1 week

Behavioral: GLP-1 stop for 1 week

GLP-1 not stop for 1 week

PLACEBO COMPARATOR

GLP-1 not stop for 1 week

Behavioral: GLP-1 not stop for 1 week

Interventions

GLP-1 not stop for 1 week BEHAVIORAL

GLP-1 not stop for 1 week

GLP-1 not stop for 1 week

GLP-1 stop for 1 week BEHAVIORAL

GLP-1 stop for 1 week

GLP-1 stop for 1 week

Eligibility Criteria

• Age: 18 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Individuals who are scheduled to undergo total colonoscopy for any reasons
• Age between 18 to 70 years.
• ECOG Performance status is 0 or 1.
• Written consent to participate in the study has been obtained.
• Outpatient department patient
• Stop at least 3 days if current using medications that promote or inhibit gastrointestinal motility.

You may not qualify if:

• Presence of severe comorbid conditions that preclude the safe performance of colonoscopy (e.g., unstable angina, recent myocardial infarction, decompensated heart failure, chronic respiratory disease, or bleeding diathesis).
• History of prior gastric, small bowel, or colorectal segmental resection (patients with isolated appendectomy are eligible).
• Family history of hereditary colorectal cancer syndromes.
• Current or prior diagnosis of inflammatory bowel disease.
• Known colorectal polyposis syndromes.
• Any other condition deemed inappropriate for study participation at the discretion of the treating physician.
• Body mass index (BMI) \> 40 kg/m².
• Diagnosis of liver cirrhosis.
• Diagnosis of Parkinson's disease.
• Diagnosis of dementia.
• Use of tricyclic antidepressants or opioid medications for more than 3 months.

Sponsors & Collaborators

• Fu Jen Catholic University Hospital: lead

Study Sites (1)

FJUH

New Taipei, Taiwan, 24352, Taiwan

RECRUITING

Central Study Contacts

Kuan I Sung

CONTACT

+886928139643; ioudanny520@hotmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: DIAGNOSTIC
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 9, 2026
• First Posted: July 30, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2028
• Last Updated: July 30, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)